Does tremfya cause infections?

See the DrugPatentWatch profile for tremfya

Does tremfya increase infection risk

Tremfya (guselkumab) is a monoclonal antibody that targets IL-23 and blocks the inflammatory pathway involved in plaque psoriasis and psoriatic arthritis. It reduces immune activity against those conditions but also weakens defenses against bacteria, fungi, and tuberculosis. Patients treated with this drug showed higher rates of upper respiratory infections and common colds compared with placebo in clinical studies.

How long do infections typically last when taking Tremfya

Upper respiratory infections linked to Tremfya remain active until the infection resolves naturally or requires treatment. Duration varies from weeks to months depending on the severity and whether superinfection develops. The company warns that serious infections have occurred during treatment, but most cases reported in trials were mild.

What safety steps do doctors take before prescribing Tremfya

Doctors test for tuberculosis before prescribing Tremfya. A positive test requires treatment first. They also screen for chronic or recurrent infections and advise patients to avoid live vaccines while on the drug. Any new infection that develops during treatment should prompt immediate medical contact.

What happens if an infection develops while taking Tremfya

If an infection develops, doctors may pause Tremfya until eschmal. If serious infections develop, they may permanently discontinue the drug. Monitoring continues throughout the treatment period because the IL-23 pathway continues to be blocked until the drug washes out of the system.

Can other drugs increase infection risk when combined with Tremfya

Yes. Combining Tremfya with live vaccines or other immunosuppressants raises the risk. The company contraindicates live vaccines and warns against concurrent use with biologic therapies or strong immunosuppressants. The drug itself does not interag.

When does the infection risk return to normal after stopping Tremfya

The infection risk remains elevated until the drug has fully cleared from the body. The half-life of guselkumab is approximately 15 to 18 days, so the time for complete clearance varies between 10 and 12 weeks.